Translating the therapeutic promise of biomolecular condensates

— from physics to physicians

Our Science

Nereid Therapeutics was born from discoveries and technologies developed by academic founder Clifford Brangwynne, Ph.D., a pioneer of the biomolecular condensate field and one of the world’s leading experts in intracellular liquid-liquid phase separation (LLPS).

If you’ve seen a lava lamp in motion, then you’ve seen LLPS in action. LLPS also occurs in living cells, where it underlies the formation and function of membrane-less compartments. It is increasingly understood that such membrane-less droplets inside cells play dynamic roles in gene regulation and in a host of disease processes. However, until now there has never been a way to systematically measure intracellular LLPS and determine the impact of therapeutics on the process. Enter Nereid Therapeutics.

New technologies developed by the Brangwynne laboratory and deployed by Nereid illuminate the formation and behavior of these droplets and enable the precise measurement of LLPS in mammalian cells. Combined with state-of-the-art proprietary microscopy and computer vision, Nereid scientists are using LLPS to discover small molecules that can modulate protein interactions found in disease states, in ways that have not been possible before.

Seeing the Science

Light-triggered LLPS

Nereid marries soft matter physics to cell biology to pioneer a new way to fight intractable diseases— cancers, neurodegenerative illnesses, and inflammatory disorders, among others. Nereid starts with unparalleled approaches to see and measure the biomolecular forces driving phase separation, amplifying insights with machine learning, and accelerating translation with state-of-the-art cell biology and medicinal chemistry. Nereid’s platform charts a new path, using physics to discover therapeutics that can modify the phase behavior of living cells.

Leadership Team

Spiros Liras, Ph.D.
Co-Founder, Interim Chief Executive Officer, and Director
Seth Harrison, M.D.
Chairman of the Board of Directors
Raj Chopra, FRCP, FRCPath, FRSB, Ph.D.
Director
Michael Ehlers, M.D., Ph.D.
Director
Laura L. Forese, M.D.
Director
Bob Hugin
Director
Rupert Vessey, FRCP, Ph.D.
Director
Cliff Brangwynne, Ph.D.
Co-Founder, Board Observer, and Scientific Advisory Board Chair
John F. Reilly, Ph.D.
Interim Chief Scientific Officer

Scientific Advisory Board

Cliff Brangwynne, Ph.D.
Professor of Chemical and Biological Engineering, Princeton University
Cigall Kadoch, Ph.D.
Associate Professor of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School
Alexander McCampbell, Ph.D.
Venture Partner, ATP
Alice Ting, Ph.D.
Professor of Genetics, Biology, and Chemistry, Stanford University
Jared Toettcher, Ph.D.
Associate Professor of Molecular Biology, Princeton University

ATP is developing the next generation of transformative life sciences companies.

News

Join Us

For more information on career opportunities at Nereid, please contact us at info@nereidtx.com